Wenqing Zhang 2 | On behalf of the WHO RSV Surveillance Group This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

No abstract

Chikungunya is a mosquito-borne virus that has shown increased prevalence in the Caribbean since October 2013. There have been several outbreaks throughout Asian and African countries over the past few decades with global travel and tourism having a major impact on the further spread of this disease. Improved policies and practices for preventative measures and epidemiological surveillance must be implemented to prevent the continued transmission of chikungunya.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-014-0043-9) contains supplementary material, which is available to authorized users.

Respiratory syncytial virus (RSV), an acute respiratory viral infection which can result in severe disease and death particularly for young infants, is being increasingly recognized as an important cause of morbidity and mortality globally. Shi et al have estimated that globally RSV-associated lower respiratory tract infection (LRTI) accounted for between 94 600 and 149 400 deaths annually. In addition, 33 million RSV-associated LRTI resulted in 3.2 million hospital admissions. 1 The authors also describe a higher burden in low-and middle-income countries (LMICs) suggesting that these populations may benefit most from a future intervention. These estimates, however, have some limitations, particularly due to lack of data from several high burden areas including sub-Saharan Africa and limited data in narrow age bands for younger children, where the burden is usually highest and in whom future interventions are likely to be targeted. Recently, significant progress has been made in the development of a range of RSV vaccine candidates, in particular for the protection